bicalutamide and Fracture, Pathologic

bicalutamide has been researched along with Fracture, Pathologic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bhattacharya, S; Chowdhury, S; Hasabou, N; Heidenreich, A; Klotz, L; Shore, ND; Siemens, DR; van Os, S; Villers, A; Wang, F	1
Chesa, N; Déniz, F; Domínguez, C; Lara, PC; Lloret, M; Naranjo, A; Ojeda, S	1

Trials

1 trial(s) available for bicalutamide and Fracture, Pathologic

Article	Year
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. The Lancet. Oncology, 2016, Volume: 17, Issue:2 Topics: Aged; Aged, 80 and over; Anemia; Anilides; Arthralgia; Back Pain; Benzamides; Constipation; Disease Progression; Disease-Free Survival; Double-Blind Method; Dyspnea; Fatigue; Fractures, Spontaneous; Heart Failure; Hot Flashes; Humans; Hydronephrosis; Hypertension; Male; Middle Aged; Myocardial Infarction; Nausea; Nitriles; Patient Dropouts; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds	2016

Article

Year

Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.

The Lancet. Oncology, 2016, Volume: 17, Issue:2

Topics: Aged; Aged, 80 and over; Anemia; Anilides; Arthralgia; Back Pain; Benzamides; Constipation; Disease Progression; Disease-Free Survival; Double-Blind Method; Dyspnea; Fatigue; Fractures, Spontaneous; Heart Failure; Hot Flashes; Humans; Hydronephrosis; Hypertension; Male; Middle Aged; Myocardial Infarction; Nausea; Nitriles; Patient Dropouts; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds

2016

Other Studies

1 other study(ies) available for bicalutamide and Fracture, Pathologic

Article	Year
Androgen deprivation in prostate cancer and the long-term risk of fracture. Actas urologicas espanolas, 2017, Volume: 41, Issue:8 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Femur Neck; Follow-Up Studies; Fractures, Spontaneous; Gonadotropin-Releasing Hormone; Humans; Interviews as Topic; Lumbar Vertebrae; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Risk Assessment; Software; Tosyl Compounds; Vitamin D	2017

Article

Year

Androgen deprivation in prostate cancer and the long-term risk of fracture.

Actas urologicas espanolas, 2017, Volume: 41, Issue:8

Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Femur Neck; Follow-Up Studies; Fractures, Spontaneous; Gonadotropin-Releasing Hormone; Humans; Interviews as Topic; Lumbar Vertebrae; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Risk Assessment; Software; Tosyl Compounds; Vitamin D

2017